All News

RheumNow Podcast square

PsA Til Death Do Us Part (1.20.2023)

Jack Cush, MD

Dr. Jack Cush reviews the highlights from the past week on RheumNow.com.

Read Article
death

AS, but not PsA, has Increased Mortality Risk

Jack Cush, MD

Inflammatory disorders are often accompanied by an increased mortality risk, either from secondary malignancy, infection or cardiovascular disease.

Read Article
SPA.spectrum.jpg

Phase III Trials Back Bimekizumab for Spondyloarthritis

Medpage Today

Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said.

Read Article
RheumNow Podcast square

Rheum Believe it Or Not (1.13.2023)

Jack Cush, MD

Dr. Jack Cush reviews the notable standouts in the news since the 1st of January.  Surprising reports on ferritin, alcohol benefits, cannabis for pain and a lower dementia risk with hydroxychloroquine.  Here are the links below.

Read Article
2022,wordle

2022 Rheumatology Year in Review

Jack Cush, MD

2022 was a year of recovery, discovery, and some losses.  While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care.

Read Article
RheumNow Podcast square

Best of 2022: EULAR 2022 Top 10 Abstracts

Jack Cush, MD

Dr. Jack Cush reviews the top abstracts from EULAR 2022  As chosen by me with the aid of the RheumNow EULAR faculty. “Top” is relative and subjective, but my criteria for inclusion are based on impact, water cooler talk potential, innovation and social media buzz.  Speaking of social media…

Read Article
AS, but not PsA, has Increased Mortality Risk A recent meta-analysis showed a significantly increased risk of overall mortality in ankylosing spondylitis (AS) but not psoriatic arthritis (PsA), largely associated with cardiovascular-specific mortality. https://t.co/gnd0bMQIui https://t.co/sWFhJAIaGH

Links:

Dr. John Cush RheumNow ( View Tweet)
Phase III Trials Back Bimekizumab for Spondyloarthritis Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said. https://t.co/pdfxa3u29k https://t.co/0wLl48Fvj6

Links:

Dr. John Cush RheumNow ( View Tweet)
Causes of Enthesitis: SpA (AS, reactive arthritis, PsA, enteropathic arthritis, ERA), JIA, but also in RA, leprosy, trauma, OA, DISH, acromegaly, fluorosis, retinoid therapy, hypo- or hyper-PTH, POEMS syndrome, X-linked hypophosphatemia https://t.co/pff2OWBT5C https://t.co/7zm2la4GtD

Links:

Dr. John Cush RheumNow ( View Tweet)
Opioids and Health Care Utilization in PsA and AS Dr Aurelie Najm discusses Abstract 0402 presented at ACR22 Convergence in Philadelphia, PA. Abstract 0402: Opioid Use and Healthcare Utilization in Adults with PsA and AS https://t.co/GsTwHbXVLm https://t.co/22i3yskUpA

Links:

Dr. John Cush RheumNow ( View Tweet)
Enthesitis portends worse SpA. Data from 749 SpA pts in REGISPONSER-AS registry found 6.1% w/achilles tendinitis at baseline. Pts w/ enthesitis had worse pain, BASDAI, mBASDAI, ASDAS-CRP scores & after 2 yrs had fewer in low dz state (16 vs 31.5%) https://t.co/sChQ4WFmlW https://t.co/BkjzxCQIGF

Links:

Dr. John Cush RheumNow ( View Tweet)
How would you treat 37yoF B27+ AS on Taltz, now pregnant?(Failed NSAIDs, TNFi's)

Dr. John Cush RheumNow ( View Tweet)

Treatment Considerations in Axial Spondyloarthritis https://t.co/GRQfk4B4QN https://t.co/xX5AYAD90c

Links:

Dr. John Cush RheumNow ( View Tweet)
For 2023 - what you going to focus on with your patients? Same ole, same ole means youre not getting better. How about focusing on 2 main messages, mine would be patient "STRENGTH" and "COMPLIANCE" (meaning more Rx education) https://t.co/fEIVYk6Z9m
Dr. John Cush RheumNow ( View Tweet)
Join us for RheumNow Live this March 18-19 in Dallas, TX! We're not like other meetings--we're answering the questions you want answered. RNL is a meeting to engage your mind and change your practice. Join us in-person or virtually! https://t.co/bMphD12Bie https://t.co/Hx0uHAIUWd

Links:

Dr. John Cush RheumNow ( View Tweet)
There is considerable overlap between fibromyalgia tender points and an enthesitis score in axial spondyloarthritis pts. 526 pts in the Predict-SpA study (53% men, 38% FM) assessed 18 TP and 13 Entheses found ICC between both scores of 0.7 https://t.co/ESmP26plDB https://t.co/7X1XhyML0f

Links:

Dr. John Cush RheumNow ( View Tweet)
Many have quoted and shown this image of Ankylosing Spondylitis in a young military recruit at age 25, 35, 45, 50 & 51yrs. This may be the MOST used slide in rheum! It comes from the work of Toronto's Dr. Hugh Little, who sadly passed away at age 58 yrs. https… https://t.co/G28YlyhX3v
Dr. John Cush RheumNow ( View Tweet)
anti-IL-23 therapy is not effective in Axial Spondyloarthritis. While ustekinumab, guselkumab and risankizumab are approved in psoriasis (& PsA for GUS, RIZ), studies of Ustekinumab and risankizumab failed to show efficacy in axSpA https://t.co/hjXEopji6r https://t.co/FwzBa2YNzb

Links:

Dr. John Cush RheumNow ( View Tweet)
Spanish SpA Registry (REGISPONSER) - 18.3% had psoriasis; w/ 3/4 of these (76%) having PSO before MSK Sxs. Pts w/ PSO before MSK Sxs had shorter dz duration, lower BMI, Less B27 & anterior uveitis, more dactylitis and ^risk PsA dx (78% vs 56%) https://t.co/Kc1n4RVe3v

Links:

Dr. John Cush RheumNow ( View Tweet)

The First Head to Head trial in Axial SpA Dr.Gensler discusses abstract L15 presented at #ACR22. L15: Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic AxSpA: A Randomized Phase IIIb Study https://t.co/J0DT1yw0vQ https://t.co/kKhFQKAy6H

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×